- Home
- GRFS vs FOUR Comparison
GRFS vs FOUR Comparison
Compare GRFS & FOUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRFS
- FOUR
- Stock Information
- Founded
- GRFS 1940
- FOUR 1999
- Country
- GRFS Spain
- FOUR United States
- Employees
- GRFS N/A
- FOUR N/A
- Industry
- GRFS Biotechnology: Pharmaceutical Preparations
- FOUR Business Services
- Sector
- GRFS Health Care
- FOUR Consumer Discretionary
- Exchange
- GRFS Nasdaq
- FOUR Nasdaq
- Market Cap
- GRFS 6.6B
- FOUR 6.9B
- IPO Year
- GRFS 2006
- FOUR 2020
- Fundamental
- Price
- GRFS $9.57
- FOUR $76.16
- Analyst Decision
- GRFS Hold
- FOUR Buy
- Analyst Count
- GRFS 1
- FOUR 20
- Target Price
- GRFS $10.30
- FOUR $109.47
- AVG Volume (30 Days)
- GRFS 522.4K
- FOUR 2.3M
- Earning Date
- GRFS 01-01-0001
- FOUR 11-06-2025
- Dividend Yield
- GRFS 1.48%
- FOUR N/A
- EPS Growth
- GRFS 132.60
- FOUR 55.45
- EPS
- GRFS 0.53
- FOUR 2.56
- Revenue
- GRFS $8,744,226,659.00
- FOUR $3,610,700,000.00
- Revenue This Year
- GRFS $5.46
- FOUR $28.63
- Revenue Next Year
- GRFS $6.69
- FOUR $24.09
- P/E Ratio
- GRFS $23.80
- FOUR $28.81
- Revenue Growth
- GRFS 9.32
- FOUR 23.86
- 52 Week Low
- GRFS $6.19
- FOUR $68.09
- 52 Week High
- GRFS $11.14
- FOUR $127.50
- Technical
- Relative Strength Index (RSI)
- GRFS 44.36
- FOUR 34.20
- Support Level
- GRFS $9.39
- FOUR $73.50
- Resistance Level
- GRFS $9.86
- FOUR $80.98
- Average True Range (ATR)
- GRFS 0.19
- FOUR 2.75
- MACD
- GRFS 0.00
- FOUR -0.23
- Stochastic Oscillator
- GRFS 33.32
- FOUR 23.13
About GRFS Grifols S.A.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
About FOUR Shift4 Payments Inc.
Shift4 Payments Inc is provider of integrated payment processing and technology solutions. The company offers software providers a single integration to an end-to-end payments offering, a powerful gateway and a robust suite of technology solutions (including cloud enablement, business intelligence, analytics, and mobile) to enhance the value of their software suites and simplify payment acceptance. The company derives maximum revenue from United States.